Rockwell Medical (NASDAQ: RMTI) is a medical products company that manufactures and distributes hemodialysis concentrates and dialysates to dialysis providers and distributors. Revenue is transactional, generated by selling hemodialysis concentrate products, including acid concentrates and bicarbonate concentrates, to dialysis clinics, hospitals, skilled nursing facilities, and home dialysis settings. As of the 10-K filed March 26, 2026, Rockwell served 294 customers, including all five of the largest dialysis providers in the United States. The company competes against Fresenius, a vertically integrated dialysis operator that manufactures its own concentrates across approximately 2,600 U.S. clinics, and Nipro, which supplies concentrates and other renal accessories. Rockwell carries a net loss position as of FY2025 and FY2024. CEO is Mark Strobeck, Ph.D., and CFO is Jesse Neri, per the March 26, 2026 filing. Products must comply with AAMI guidelines and cGMP regulations, and at least one product, the Dry Acid Concentrate Mix System, holds 510(k) FDA clearance.

Revenue model

Transactional product sales of hemodialysis concentrates and ancillary dialysis supplies to dialysis providers and distributors in the United States and internationally.

Products and services

Hemodialysis concentrates and dialysates including: Dri-Sate dry powder acetic acid concentrate, RenalPure liquid acid concentrate (55-gallon drums and one-gallon jugs), RenalPure bicarbonate concentrate (dry powder), SteriLyte liquid bicarbonate concentrate (used in acute care settings), single-use bicarbonate cartridges (720g and 900g canisters, sold in ten-count cases), and the Dry Acid Concentrate Mix System (510(k) approved).

Customers and end markets

294 customers as of the 10-K filed March 26, 2026, including all five leading U.S. dialysis providers. End markets include freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, and home dialysis patients. End-stage kidney disease patients receiving hemodialysis are the ultimate consumers. Medicare and Medicaid fund the majority of dialysis costs in the United States, making government reimbursement a material demand driver.

Value-chain role

Manufacturer and distributor of hemodialysis concentrate products. Manufactures products per AAMI guidelines and cGMP regulations. Products are shipped to dialysis clinics where they are diluted with purified water on-site to create dialysate used in hemodialysis machines.

Geographic exposure

Primary market is the United States. The filing references sales to distributors and providers abroad, but no geographic revenue breakdown is provided in the excerpts.

Competitors

Fresenius (Fresenius Kidney Care), Nipro

Source: SEC 10-K, filed 2026-03-26

Industry: Pharmaceutical Preparations Peers: Nexgel Inc SURGALIGN HOLDINGS, INC. Axe Compute Inc CHEMBIO DIAGNOSTICS, INC. Rapid Therapeutic Science Laboratories, Inc. Innovative Eyewear Inc Sharps Technology Inc PROJECT SAGE OLDCO, INC.